Fezolinetant Hot Flash Drug Linked to Tumor Risk: New Review

Fezolinetant’s Cancer-Safety Question Meets a New Dual-Blocker Rival in the Neurokinin Hot-Flash Race

Meta-analyses of clinical trial data now show a consistent signal: fezolinetant, the first nonhormonal drug approved (2023, FDA and EMA) for moderate to severe menopausal hot flashes, is associated with a significantly increased rate of nonbenign neoplasms — tumors that are not simply benign growths. A 2026 review by researchers at the University of Namur (Boretti, Dogné, and Douxfils) in the Journal of the Endocrine Society lays out the clinical evidence and two biological mechanisms that could explain it. At the same time, a second drug, elinzanetant, has arrived with a different receptor-blocking strategy and, so far, a cleaner safety record.

The KNDy Neuron System: Why Blocking One Receptor Quiets Hot Flashes

Hot flashes and night sweats — collectively vasomotor symptoms, or VMS — originate in a small cluster of hypothalamic cells called KNDy neurons. During menopause, falling estrogen widens the thermoneutral zone, the temperature range your body tolerates without reacting. KNDy neurons, which release neurokinin B alongside two other signaling peptides, act as the relay that translates this estrogen decline into sudden heat-dumping episodes.

Fezolinetant blocks the neurokinin-3 receptor (NK3R), the main receptor for neurokinin B. That calms the KNDy-driven signal to the brain’s cooling circuits and reduces how often hot flashes fire. Elinzanetant blocks NK3 too, but adds a second target: the neurokinin-1 receptor (NK1R). In the OASIS phase 3 trials, this dual blockade produced a 65.2–67.0% reduction in hot-flash frequency by week 12, with a clinically meaningful improvement in the PROMIS sleep disturbance score — a benefit that a fezolinetant cross-over comparison suggests may reflect elinzanetant’s NK1 arm, since NK1R also participates in mood and sleep regulation.

Why Fezolinetant’s Tumor Signal Warrants Attention: Kisspeptin and Receptor Compensation

Boretti and colleagues at Namur’s NARILIS pharmacology unit describe two mechanisms by which NK3R blockade might, in theory, promote tumor behavior. Neither is proven causation — the authors are explicit that these are mechanistic concerns, not established facts. But both are biologically grounded.

Kisspeptin suppression. NK3R signaling normally drives the secretion of kisspeptin, a peptide known best for its role in reproductive hormone release but originally discovered as a metastasis suppressor: it is expressed widely in the body and works to hold cancer cells in place. Blocking NK3R reduces kisspeptin output. Less of an antimetastasis peptide circulating in tissues is a straightforward reason for concern, even if the magnitude of the effect is unknown.

NK1R compensation. Receptor systems rarely act in isolation. When one receptor is blocked long-term, related pathways often compensate. Chronically inhibiting NK3R, the Namur team argues, may shift signaling toward NK1R — and NK1R activation has been tied directly to tumor proliferation, new blood-vessel growth feeding tumors (angiogenesis), and metastasis. Notably, cancer researchers have spent years developing NK1R antagonists as potential antitumor agents, which makes unopposed NK1R activation an unwelcome side effect of a drug that doesn’t touch that receptor.

The clinical side of the picture matters as much as the theory. Fezolinetant’s efficacy and general safety were established in the SKYLIGHT and MOONLIGHT trial programs, but regulatory agencies initially dismissed the neoplasm signal. Meta-analyses and pooled analyses that followed — the reason this 2026 review exists — consistently showed a significant increase in nonbenign neoplasms versus comparators. Dismissal of early signals has historically proven costly in pharmacology, and the authors argue this one now deserves formal long-term investigation rather than reassurance.

What Elinzanetant’s Dual Design Changes — and What It Doesn’t

At first glance, elinzanetant looks like a mechanistic answer to the fezolinetant concern. By blocking NK1R alongside NK3R, it removes the very receptor whose compensatory activation is hypothesized to drive tumor growth in fezolinetant users. The OASIS program also reported sustained efficacy through longer follow-up and a favorable long-term liver safety profile — relevant because hepatic injury was fezolinetant’s other flagged concern, one that already carries FDA liver-monitoring requirements.

But an honest reading stops short of declaring elinzanetant safer on the cancer front. Its trials were not designed or powered to detect neoplasm risk, and no head-to-head comparison with fezolinetant on cancer outcomes exists. The sleep-quality advantage suggested by indirect cross-trial comparisons is likewise exactly that — indirect. Teli and Teli’s assessment in the Journal of Menopausal Medicine calls for head-to-head trials to confirm any real advantage. For now, the honest statement is: elinzanetant’s mechanism is theoretically reassuring, and its trial data show no liver signal — but absence of evidence over limited follow-up is not evidence of absence.

Practical Guidance for Choosing Between Options Today

If you experience moderate to severe hot flashes and are weighing treatments, the neurokinin class offers genuinely effective nonhormonal options — but the choice now involves more nuance than it did in 2023.

• Discuss the neoplasm signal with your clinician if you currently take fezolinetant (Veozah/Veoza), especially if you have a personal or family history of cancer. The signal is statistical, not deterministic, and regulators have not withdrawn the drug — but informed consent should reflect the pooled data, not just the original trials.
• Ask about elinzanetant if sleep disruption accompanies your hot flashes; its NK1 blockade targets both, and its liver-safety record to date is favorable.
• Remember the hormonal alternatives. For women without contraindications, transdermal estrogen remains a well-characterized option — our coverage of why transdermal estrogen is now the top-choice delivery route and of 2026 hormone-therapy safety reviews puts the risk-benefit picture side by side.
• Keep duration in mind. Hot flashes can persist for a decade or longer, meaning many users will take these drugs for years — precisely the timeline over which a small neoplastic risk, if real, would matter most. Longer trials are the only way to settle it.

Frequently Asked Questions

Do neurokinin receptor antagonists actually cause cancer?

Not proven. Pooled data show a significant increase in nonbenign neoplasms among fezolinetant users, and plausible mechanisms exist, but a causal link has not been established — long-term studies are needed to determine whether the association is real.

Is elinzanetant safer than fezolinetant?

Elinzanetant blocks NK1 in addition to NK3, which theoretically avoids the compensatory NK1R activation flagged for fezolinetant, and it shows a favorable liver-safety record. However, no head-to-head cancer-safety comparison exists, so superiority remains unconfirmed.

How well do these drugs actually work for hot flashes?

Elinzanetant reduced hot-flash frequency by 65.2–67.0% by week 12 in the OASIS phase 3 trials, with measurable improvements in sleep disturbance. Fezolinetant’s efficacy was established separately in the SKYLIGHT and MOONLIGHT programs.

Should I stop taking fezolinetant?

No one should stop or switch based on a statistical signal alone. Talk with your clinician about your individual cancer-risk profile, the alternatives available, and how long you expect to need treatment before making any change.

For now, the neurokinin antagonist story is one of real therapeutic progress shadowed by an unresolved safety question. Fezolinetant and elinzanetant deliver meaningful relief to women who cannot or prefer not to use hormone therapy — but the Namur review makes clear that the KNDy–kisspeptin–neurokinin pathway has consequences beyond temperature control, and regulators, clinicians, and patients deserve data that follow users for years, not months.

Sources:
https://pubmed.ncbi.nlm.nih.gov/42137787/
https://pubmed.ncbi.nlm.nih.gov/42045091/
https://pubmed.ncbi.nlm.nih.gov/42024036/
https://pubmed.ncbi.nlm.nih.gov/41997569/
https://pubmed.ncbi.nlm.nih.gov/41981275/